Tyra Widens Loss as Clinical-Trial Spending Rises
Research-and-development expenses climbed 61% to $39.2 million as Tyra advanced dabogratinib trials.
Tyra Biosciences (TYRA), a clinical-stage biotechnology company, widened its second-quarter net loss to $45.6 million as development spending increased.
The results reflected heavier investment in dabogratinib as Tyra expanded a pediatric study and enrolled more patients in a separate cancer trial. The net loss grew about 62% from $28.1 million a year earlier.
Research-and-development expenses rose from $24.3 million, driven primarily by dabogratinib trial activity and higher personnel, facilities and other costs. General-and-administrative expenses increased 38% to $9.8 million, mainly because of higher compensation and other personnel costs.
Tyra expanded its BEACH301 study to a fifth dose level of 0.625 mg/kg after clearing four dose levels without notable safety events. Initial safety-sentinel data covering the first five dose levels and about 25 children are expected at the end of the first quarter of 2027.
Enrollment in the SURF302 study exceeded 40 patients. Initial results expected in September 2026 are set to include safety data from more than 40 patients and efficacy data from more than 20 patients across the 50-milligram and 60-milligram once-daily cohorts.
Tyra also amended its at-the-market sales agreement in August, adding capacity for as much as $250 million in potential common-stock issuance as its clinical programs advanced.